N8 Medical, LLC (N8 Medical) is a clinical-stage medical device company structured around development of medical devices that incorporate a novel class of active (proprietary) compounds called ceragenins - synthetic, non-peptide small molecule mimetics of endogenous host defense peptides. The public health and economic burden associated with device-related infections and other complications associated with medical devices factors to multi-billions of dollars. The proprietary ceragenin compounds utilized by N8 Medical - engaging the firm's CeraShiled (TM) technology - can impart unique properties to medical devices to include antimicrobial, anti-inflammatory and other therapeutic properties representing both a major business development opportuity and an important health benefit both in terms of improved patient outcomes and a likely lowering of theoverall cost of care. In Spring 2019, N8 announced the First-in-Human Use of its CeraShield™ Endotracheal Tube
